Liquid biopsy in the clinical management of bladder cancer: current status and future developments

Erik Kouba, Antonio Lopez-Beltran, Rodolfo Montironi, Francesco Massari, Kun Huang, Matteo Santoni, Michal Chovanec, Michael Cheng, Marina Scarpelli, Jie Zhang, Alessia Cimadamore, Liang Cheng

Research output: Contribution to journalReview article

Abstract

Introduction: The use of liquid biopsy on the blood from solid malignancies provides a convenient way of detecting actionable mutations, monitoring treatment response, detecting early recurrence and prognosticating outcomes. The aim of this review is to discuss the current status and future direction of serum biomarkers in the clinical management of urinary bladder cancer. Areas covered: This review provides an overview of blood liquid biopsy and bladder cancer using methods of circulating tumors cells, circulating RNA, serum metabolites and cell-free DNA. Recent clinical studies and advances in methodology are emphasized. We performed a literature search using PMC/PubMed with keywords including ‘liquid biopsy’, ‘circulating tumor DNA’, ‘cell-free DNA’, ‘biomarkers’, ‘bladder cancer’ ‘precision medicine’. Additional articles were obtained from the cited references of key articles. An emphasis was placed on recent studies published since 2018. Expert opinion: Liquid biopsies represent a potential biomarker using cell-free DNA, metabolomic profiles of altered cellular metabolism, circulating cancer cells and RNA. Despite displaying tremendous clinical promise, the current status of the blood liquid biopsies has not reached fruition. However, future investigations should lead the evolution of liquid biomarker into clinical utility for the management of bladder cancer.

Original languageEnglish (US)
JournalExpert Review of Molecular Diagnostics
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Urinary Bladder Neoplasms
Biopsy
Biomarkers
Circulating Neoplastic Cells
DNA
RNA
Precision Medicine
Metabolomics
Expert Testimony
Serum
PubMed
Neoplasms
Recurrence
Mutation
Therapeutics

Keywords

  • biomarker
  • bladder cancer
  • cell-free DNA
  • circulating tumor cells
  • Liquid biopsy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Liquid biopsy in the clinical management of bladder cancer : current status and future developments. / Kouba, Erik; Lopez-Beltran, Antonio; Montironi, Rodolfo; Massari, Francesco; Huang, Kun; Santoni, Matteo; Chovanec, Michal; Cheng, Michael; Scarpelli, Marina; Zhang, Jie; Cimadamore, Alessia; Cheng, Liang.

In: Expert Review of Molecular Diagnostics, 01.01.2019.

Research output: Contribution to journalReview article

Kouba, E, Lopez-Beltran, A, Montironi, R, Massari, F, Huang, K, Santoni, M, Chovanec, M, Cheng, M, Scarpelli, M, Zhang, J, Cimadamore, A & Cheng, L 2019, 'Liquid biopsy in the clinical management of bladder cancer: current status and future developments', Expert Review of Molecular Diagnostics. https://doi.org/10.1080/14737159.2019.1680284
Kouba, Erik ; Lopez-Beltran, Antonio ; Montironi, Rodolfo ; Massari, Francesco ; Huang, Kun ; Santoni, Matteo ; Chovanec, Michal ; Cheng, Michael ; Scarpelli, Marina ; Zhang, Jie ; Cimadamore, Alessia ; Cheng, Liang. / Liquid biopsy in the clinical management of bladder cancer : current status and future developments. In: Expert Review of Molecular Diagnostics. 2019.
@article{0f2014303045461a8a375c034fde799d,
title = "Liquid biopsy in the clinical management of bladder cancer: current status and future developments",
abstract = "Introduction: The use of liquid biopsy on the blood from solid malignancies provides a convenient way of detecting actionable mutations, monitoring treatment response, detecting early recurrence and prognosticating outcomes. The aim of this review is to discuss the current status and future direction of serum biomarkers in the clinical management of urinary bladder cancer. Areas covered: This review provides an overview of blood liquid biopsy and bladder cancer using methods of circulating tumors cells, circulating RNA, serum metabolites and cell-free DNA. Recent clinical studies and advances in methodology are emphasized. We performed a literature search using PMC/PubMed with keywords including ‘liquid biopsy’, ‘circulating tumor DNA’, ‘cell-free DNA’, ‘biomarkers’, ‘bladder cancer’ ‘precision medicine’. Additional articles were obtained from the cited references of key articles. An emphasis was placed on recent studies published since 2018. Expert opinion: Liquid biopsies represent a potential biomarker using cell-free DNA, metabolomic profiles of altered cellular metabolism, circulating cancer cells and RNA. Despite displaying tremendous clinical promise, the current status of the blood liquid biopsies has not reached fruition. However, future investigations should lead the evolution of liquid biomarker into clinical utility for the management of bladder cancer.",
keywords = "biomarker, bladder cancer, cell-free DNA, circulating tumor cells, Liquid biopsy",
author = "Erik Kouba and Antonio Lopez-Beltran and Rodolfo Montironi and Francesco Massari and Kun Huang and Matteo Santoni and Michal Chovanec and Michael Cheng and Marina Scarpelli and Jie Zhang and Alessia Cimadamore and Liang Cheng",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/14737159.2019.1680284",
language = "English (US)",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Liquid biopsy in the clinical management of bladder cancer

T2 - current status and future developments

AU - Kouba, Erik

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

AU - Massari, Francesco

AU - Huang, Kun

AU - Santoni, Matteo

AU - Chovanec, Michal

AU - Cheng, Michael

AU - Scarpelli, Marina

AU - Zhang, Jie

AU - Cimadamore, Alessia

AU - Cheng, Liang

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: The use of liquid biopsy on the blood from solid malignancies provides a convenient way of detecting actionable mutations, monitoring treatment response, detecting early recurrence and prognosticating outcomes. The aim of this review is to discuss the current status and future direction of serum biomarkers in the clinical management of urinary bladder cancer. Areas covered: This review provides an overview of blood liquid biopsy and bladder cancer using methods of circulating tumors cells, circulating RNA, serum metabolites and cell-free DNA. Recent clinical studies and advances in methodology are emphasized. We performed a literature search using PMC/PubMed with keywords including ‘liquid biopsy’, ‘circulating tumor DNA’, ‘cell-free DNA’, ‘biomarkers’, ‘bladder cancer’ ‘precision medicine’. Additional articles were obtained from the cited references of key articles. An emphasis was placed on recent studies published since 2018. Expert opinion: Liquid biopsies represent a potential biomarker using cell-free DNA, metabolomic profiles of altered cellular metabolism, circulating cancer cells and RNA. Despite displaying tremendous clinical promise, the current status of the blood liquid biopsies has not reached fruition. However, future investigations should lead the evolution of liquid biomarker into clinical utility for the management of bladder cancer.

AB - Introduction: The use of liquid biopsy on the blood from solid malignancies provides a convenient way of detecting actionable mutations, monitoring treatment response, detecting early recurrence and prognosticating outcomes. The aim of this review is to discuss the current status and future direction of serum biomarkers in the clinical management of urinary bladder cancer. Areas covered: This review provides an overview of blood liquid biopsy and bladder cancer using methods of circulating tumors cells, circulating RNA, serum metabolites and cell-free DNA. Recent clinical studies and advances in methodology are emphasized. We performed a literature search using PMC/PubMed with keywords including ‘liquid biopsy’, ‘circulating tumor DNA’, ‘cell-free DNA’, ‘biomarkers’, ‘bladder cancer’ ‘precision medicine’. Additional articles were obtained from the cited references of key articles. An emphasis was placed on recent studies published since 2018. Expert opinion: Liquid biopsies represent a potential biomarker using cell-free DNA, metabolomic profiles of altered cellular metabolism, circulating cancer cells and RNA. Despite displaying tremendous clinical promise, the current status of the blood liquid biopsies has not reached fruition. However, future investigations should lead the evolution of liquid biomarker into clinical utility for the management of bladder cancer.

KW - biomarker

KW - bladder cancer

KW - cell-free DNA

KW - circulating tumor cells

KW - Liquid biopsy

UR - http://www.scopus.com/inward/record.url?scp=85074352226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074352226&partnerID=8YFLogxK

U2 - 10.1080/14737159.2019.1680284

DO - 10.1080/14737159.2019.1680284

M3 - Review article

C2 - 31608720

AN - SCOPUS:85074352226

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

ER -